Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events.

导出 OA

翻译打印收藏纠错

作者： Tatsuo,Kanda ^[1] ; Shin,Yasui ^[2] ; Masato,Nakamura ^[2] ; Shingo,Nakamoto ^[2] ; Koji,Takahashi ^[2] ; Shuang,Wu ^[3] ; Reina,Sasaki ^[2] ; Yuki,Haga ^[2] ; Sadahisa,Ogasawara ^[2] ; Tomoko,Saito ^[2] ; Kazufumi,Kobayashi ^[2] ; Soichiro,Kiyono ^[2] ; Yoshihiko,Ooka ^[2] ; Eiichiro,Suzuki ^[2] ; Tetsuhiro,Chiba ^[2] ; Hitoshi,Maruyama ^[2] ; Mitsuhiko,Moriyama ^[2] ; Naoya,Kato ^[2]

作者单位： Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine, Itabashi-ku, Tokyo 173-8610, Japan. ^[1] Department of Gastroenterology, Chiba University, Graduate School of Medicine, Chuo-ku, Chiba 260-8670, Japan. ^[2] Department of Molecular Virology, Chiba University, Graduate School of Medicine, Chuo-ku, Chiba 260-8670, Japan. ^[3]

关键词 direct-acting antiviral failure hepatitis C virus ledipasvir ombitasvir resistance-associated substitutions

DOI 10.18632/oncotarget.24620

PMID 29662642

发布时间 2022-03-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交